# US 2024/0199750 A1 · Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199750 A1
- Document ID: US20240199750A1
- Status: Published application
- Kind: A1
- Application number: 18/283,385
- Filed: 2022-03-24
- Published: 2024-06-20
- Earliest claimed: 2021-03-26
- Applicants: Innate Pharma
- Inventors: Stephanie CORNEN; Laurent GAUTHIER; Yannis MOREL; Olivier DEMARIA
- Web page: https://patentgrep.com/patent/US20240199750A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 38/20: Interleukins [IL]
- A61P 35/00: Antineoplastic agents
- C07K 14/54: Interleukins [IL]
- C07K 14/5418: {IL-7}
- C07K 14/5434: {IL-12}
- C07K 14/5443: {IL-15}
- C07K 14/55: IL-2
- C07K 14/56: IFN-alpha
- C07K 14/565: IFN-beta
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- C07K 16/2887: {against CD20}
- C07K 16/30: from tumour cells
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/55: Fab or Fab'
- C07K 2317/60: characterized by non-natural combinations of immunoglobulin fragments
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Multi-specific proteins that bind to NKp46 and a cytokine receptor on NK cells, and optionally that further bind CD16A on NK cells, and that also bind to an antigen of interest (e.g. a cancer antigen) on a target cell (e.g. a cancer cell). The multi-specific proteins are capable of increasing NK cell cytotoxicity toward a target cell that expresses the antigen of interest (e.g., a cell that contributes to disease, a cancer cell).

## Claims

### Claim 1

A multispecific protein which is capable of binding to an antigen of interest expressed by a target cell, and which is further capable of binding to NKp46, a cytokine receptor and optionally CD16A at the surface of an NK cell, and which multispecific protein is capable of potentiating NK cell cytotoxicity toward a target cell expressing an antigen of interest, the multispecific protein comprising:
(a) an antigen binding domain (ABD) that binds to an antigen of interest;
(b) an ABD that binds to a human NKp46 polypeptide;
(c) an Fc domain, or a portion an Fc domain capable of binding FcRn; and
(d) an ABD that binds a human cytokine receptor present on NK cells,
wherein:
the ABD that binds to a human NKp46 polypeptide is connected to the Fc domain, optionally via an Ig-derived or non-Ig-derived polypeptide linker, and wherein the the ABD that binds a human cytokine receptor is connected, via a polypeptide linker, to the ABD that binds to a human NKp46 polypeptide or to the Fc domain.

### Claim 2 (depends on 1)

The protein of claim 1, wherein the protein has only one ABD that binds to an antigen of interest, such that the protein binds to the antigen of interest monovalently, optionally further wherein the protein has only one ABD that binds to a human NKp46 polypeptide, only one ABD that binds a cytokine receptor, and only one Fc domain dimer.

### Claim 3 (depends on 1, 2)

The protein of claim 1 or 2, wherein the ABD that binds the cytokine receptor is connected via a polypeptide linker to the ABD that binds NKp46.

### Claim 4 (depends on 1, 2, 3)

The protein of claims 1, 2 or 3, wherein the ABD that binds to a human NKp46 polypeptide and the ABD that binds a human cytokine receptor, and optionally further the Fc domain, are positioned within the multispecific protein in series with respect to the N- and C-termini of the multispecific protein.

### Claim 5

The protein of any one of the above claims, wherein the ABD that binds to a human NKp46 polypeptide and the ABD that binds a human cytokine receptor, and optionally the Fc domain, are configured to be capable of adopting a membrane-planar binding conformation such that the protein is capable of binding to NKp46 and the cytokine receptor, and optionally further CD16A, on the surface of an NK cell.

### Claim 6

The protein of any one of the above claims, wherein the ABD that binds a human cytokine is connected to the ABD that binds to a human NKp46 polypeptide or the Fc domain by a linker peptide having 20 or less than 20 amino acid residues, optionally less than 15 amino acid residues, optionally less than 10 amino acid residues, optionally between 5 and 15 residues, optionally between 5 and 10 residues, optionally between 3 and 5 residues.

### Claim 7

The protein of any one of the above claims, wherein the ABD that binds to a human NKp46 polypeptide is connected to the Fc domain by a linker peptide having 15 or less than 15 amino acid residues, optionally less than 10 amino acid residues, optionally between 4 and 15 residues, optionally between 3 and 10 residues, optionally between 4 and 5 residues.

### Claim 8

The protein of any one of the above claims, wherein the ABD that binds to a human NKp46 polypeptide is connected to the Fc domain by an immunoglulin-derived linker peptide having 20 or less than 20 amino acid residues, optionally less than 15 amino acid residues, optionally between 4 and 15 residues, optionally between 4 and 10 residues, optionally between 3 and 5 residues, optionally wherein the linker comprises the amino acid sequence RTVA.

### Claim 9

The protein of any one of the foregoing claims, wherein the ABD that binds NKp46 is interposed between the Fc domain and the ABD that binds the cytokine receptor.

### Claim 10

The protein of any one of the foregoing claims, wherein each ABD comprises a VH and/or VL domain or fragment thereof, optionally wherein a VH and/or VL comprises three complementary determining regions (CDR1, CDR2 and CDR-3).

### Claim 11

A protein comprising an ABD that binds to a human NKp46 polypeptide fused, optionally via a domain linker having 15 or less than 15 amino acid residues, to a cytokine that binds a receptor expressed at the surface of an NK cell.

### Claim 12

The protein of claim of any one of the above claims, wherein the ABD that binds to a human NKp46 polypeptide comprises a VH and/or VL domain that binds to the D1/D2 junction of the human NKp46 polypeptide, and wherein the cytokine is a modified IL-2 polypeptide.

### Claim 13 (depends on 11, 12)

The protein of claim 11 or 12, wherein the ABD that binds to a human NKp46 polypeptide is fused at its C-terminus, via a domain linker, to the N-terminus of the cytokine, optionally wherein the ABD that binds to a human NKp46 polypeptide has an scFv or a Fab structure.

### Claim 14

The protein of any one of the foregoing claims, wherein the protein is a heterodimer comprising a first and second polypeptide chain, or a heterotimer comprising a first, second and third polypeptide chain.

### Claim 15

The protein of any one of the foregoing claims, comprising:
(i) a first polypeptide chain comprising, from N- to C-terminal, a variable domain that binds NKp46, a human CH1 or CL constant domain, optionally a domain linker, and a wild-type or variant IL-2, IL-15, IL-21, IL-7, IL-27, IL-12, IL-18, IFN-α or IFN-β polypeptide, and
(ii) a second polypeptide chain comprising, from N- to C-terminal, a variable domain that associates with the variable domain of (i) to form a NKp46-binding domain, and a human CH1 or CL constant domain;
wherein one of the constant domains of (i) and (ii) is a CH1 and the other is a CL such that the constants domains of (i) and (ii) associate by CH1-CL dimerization.

### Claim 16

The protein of any one of the foregoing claims, wherein the protein comprises a NKp46 ABD-cytokine unit having a domain arrangement:
wherein:
Va-2 and Vb-2 are each a VH domain or a VL domain, wherein one of Va-2 and Vb-2 is a VH and the other is a VL and wherein Va-2 and Vb-2 form a second ABD that binds NKp46;
CH1 is a human immunoglobulin CH1 domain and CL is a human light chain constant domain;
one of (CH1 or CL)a and (CH1 or CL)b is a CH1 and the other is a CL such that a (CH1/CL) pair is formed;
L is a domain linker; and
Cyt is a cytokine polypeptide or portion thereof that binds to a cytokine receptor present on NK cells, optionally wherein Cyt is a wild-type or variant human IL-2, IL-15, IL-21, IL-7, IL-27, IL-12, IL-18, IFN-α or IFN-β polypeptide.

### Claim 17

The protein of any one of the foregoing claims, comprising:
(a) (i) a first polypeptide chain comprising, from N- to C-terminal, an NKp46-binding domain or portion thereof comprising a variable domain comprising an amino acid sequence at least 80%, 90%, 95%, 98% or 99% identical to an amino acid sequence of any of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 112, 113, 115, 116, 117, 119, 120, 121, 123, 124, 125, 127, 128, 129 or 236-313, a human CH1 or CL constant domain, a domain linker, and a wild-type or variant IL-2, IL-15, IL-21, IL-7, IL-27, IL-12, IL-18, IFN-α or IFN-β polypeptide comprising an amino acid sequence at least 80%, 90%, 95%, 98% or 99% identical to an amino acid sequence of any of SEQ ID NOS: 404-439 or to a fragment thereof of at least 40, 50, 60, 80 or 100 contiguous amino acids thereof, and (ii) a second polypeptide chain comprising, from N- to C-terminal, a variable domain that associates with the variable domain of (i) to form a NKp46-binding domain wherein the variable domain comprises an amino acid sequence at least 80%, 90%, 95%, 98% or 99% identical to an amino acid sequence of any of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 114, 118, 122, 126, 130 or 314-403, and a human CH1 or CL constant domain; or
(b) (i) a first polypeptide chain comprising, from N- to C-terminal, an NKp46-binding domain or portion thereof comprising a variable domain comprising an amino acid sequence at least 80%, 90%, 95%, 98% or 99% identical to an amino acid sequence of any of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 114, 118, 122, 126, 130 or 314-403, a human CH1 or CL constant domain, a domain linker, and a wild-type or variant IL-2, IL-15, IL-21, IL-7, IL-27, IL-12, IL-18, IFN-α or IFN-β polypeptide comprising an amino acid sequence at least 80%, 90%, 95%, 98% or 99% identical to an amino acid sequence of any of SEQ ID NOS: 404-439 or to a fragment thereof of at least 40, 50, 60, 80 or 100 contiguous amino acids thereof, and
(ii) a second polypeptide chain comprising, from N- to C-terminal, a variable domain that associates with the variable domain of (i) to form a NKp46-binding domain wherein the variable domain comprises an amino acid sequence at least 80%, 90%, 95%, 98% or 99% identical to an amino acid sequence of any of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 112, 113, 115, 116, 117, 119, 120, 121, 123, 124, 125, 127, 128, 129 or 236-313, and a human CH1 or CL constant domain.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The protein of any one of claims 1-13, wherein the protein comprises a polypeptide comprising a NKp46 ABD-cytokine unit having a domain arrangement
L1-Va-2-L2-Vb-2-L3-Cyt
wherein:
Va-2 and Vb-2 are each a VH domain or a VL domain, wherein one of Va-2 and Vb-2 is a VH and the other is a VL and wherein Va-2 and Vb-2 form a second ABD that binds NKp46; L1, L2 and L3 are each a domain linker, wherein L1, L2 and L3 can be different or the same, wherein L1 is a domain linker connecting the NKp46 ABD-cytokine unit to the rest of the protein; and Cyt is a cytokine polypeptide or portion thereof that binds to a cytokine receptor present on NK cells, optionally wherein Cyt is a wild-type or variant human IL-2, IL-15, IL-21, IL-7, IL-27, IL-12, IL-18, IFN-α or IFN-β polypeptide.

### Claim 19

The protein of any one of the foregoing claims, wherein the ABD that binds a cytokine receptor comprises an IL-2 polypeptide displaying reduced binding to CD25 compared to a wild-type human IL-2 polypeptide.

### Claim 20

The protein of any one of the foregoing claims, wherein the protein or the ABD that binds to a human NKp46 polypeptide binds human NKp46 polypeptide with a KD of between 1 and 100 nM, as determined by SPR and/or wherein the protein or the cytokine binds the human cytokine receptor with a KD of between 10 nM and 1 μM, as determined by SPR.

### Claim 21

The protein of any one of the above claims, wherein the multispecific polypeptide binds to a human Fcγ receptor, optionally CD16A, with an affinity for monovalent binding, as assessed by surface plasmon resonance, that is substantially equivalent to that of a full-length wild type human IgG1 antibody.

### Claim 22

The protein of any one of the above claims, wherein the protein, immobilized on a surface, binds a soluble human CD16A polypeptide with a KD for monovalent binding that is no more than 2000 nM, optionally 1000-2000 nM, optionally 1100 or 1300 nM, as determined by surface plasmon resonance using Biacore.

### Claim 23

The protein of any one of the foregoing claims, wherein the cytokine receptor is a receptor present at the surface of NK cells and that associates with the common γ-chain (γC; CD132), optionally further wherein wherein the cytokine receptor is the mid-affinity IL-2/IL-15Rβ receptor (CD122) or IL-21R (CD360), and optionally wherein the cytokine polypeptide is IL-2, IL-15 or IL-21.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23)

The protein of any one of claims 1-17 or 19-23, wherein the protein is an isolated heterotrimeric polypeptide comprising:
(a) a first polypeptide chain comprising, from N- to C-terminus, a first variable domain (V), a first CH1 of CK constant region, a Fc domain or portion thereof, a second variable domain (V) and a second CH1 of CK constant region;
(b) a second polypeptide chain comprising, from N- to C-terminus, a first variable domain (V), a CH1 or CK constant region, and a Fc domain or portion thereof, wherein the V domain and CH1 or Cκ constant region are selected to be complementary to the first V domain and first CH1 or Cκ constant region of the first polypeptide chain such that the first and second polypeptides form a CH1-Cκ heterodimer in which the first variable domain of the first polypeptide chain and the first variable domain of the second polypeptide form a first antigen binding domain that binds the antigen of interest; and
(c) a third polypeptide chain comprising, from N- to C-terminus, a variable domain (V) and a CH1 or CK constant region, wherein the V domain and CH1 or Cκ constant region are selected to be complementary to the second V domain and second CH1 or Cκ constant region of the first polypeptide chain such that the first and third polypeptides form a CH1-Cκ heterodimer in which the second variable domain of the first polypeptide chain and the variable domain of the third polypeptide form a second antigen binding domain that binds NKp46, and
wherein one of the first or third polypeptide chains further comprises a cytokine, optionally an IL-2, IL-15, IL-21, IL-7, IL-27, IL-12, IL-18, IFN-α or IFN-β polypeptide, optionally an IL-2v or IL15v, covalently attached, optionally via a domain linker, to its C-terminus.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24)

The multispecific protein of claims 1-17 or 19-24, wherein the protein is a heterotrimer having a polypeptide chain 1, 2 and 3:
wherein:
Va-1, Vb-1, Va-2 and Vb-2 are each a VH domain or a VL domain, wherein one of Va-1 and Vb-1 is a VH and the other is a VL and wherein Va-1 and Vb-1 form a first antigen binding domain (ABD) that binds an antigen of interest, wherein one of Va-2 and Vb-2 is a VH and the other is a VL and wherein Va-2 and Vb-2 form a second ABD that binds NKp46;
CH1 is a human heavy chain constant domain 1 and CL is a human light chain constant domain;
one of (CH1 or CL)a and (CH1 or CL)c is a CH1 and the other is a CL such that a (CH1/CL) pair is formed;
one of (CH1 or CL)b and (CH1 or CL)d is a CH1 and the other is a CL such that a (CH1/CL) pair is formed;
Hinge is an immunoglobulin hinge region or portion thereof;
L1 and L2 are each a domain linker, wherein L1 and L2 can be different or the same;
CH2 and CH3 are human immunoglobulin CH2 and CH3 domains, respectively; and
Cyt is a cytokine polypeptide or portion thereof that binds to a cytokine receptor present on NK cells, optionally wherein Cyt is a wild-type or variant human IL-2, IL-15, IL-21, IL-7, IL-27, IL-12, IL-18, IFN-α or IFN-β polypeptide.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25)

The protein of any one of claims 1-17 or 19-25, having the domain arrangement:

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24)

The protein of any one of claims 1-17 or 19-24, wherein the protein is a heterotrimer having a polypeptide chain 1, 2 and 3:
wherein:
Va-1, Vb-1, Va-2 and Vb-2 are each a VH domain or a VL domain, wherein one of Va-1 and Vb-1 is a VH and the other is a VL and wherein Va-1 and Vb-1 form a first antigen binding domain (ABD) that binds an antigen of interest, wherein one of Va-2 and Vb-2 is a VH and the other is a VL and wherein Va-2 and Vb-2 form a second ABD that binds NKp46;
CH1 is a human heavy chain constant domain 1 and CL is a human light chain constant domain;
one of (CH1 or CL)a and (CH1 or CL)c is a CH1 and the other is a CL such that a (CH1/CL) pair is formed;
one of (CH1 or CL)b and (CH1 or CL)d is a CH1 and the other is a CL such that a (CH1/CL) pair is formed;
Hinge is an immunoglobulin hinge region or portion thereof;
L1 and L2 are each a domain linker, wherein L1 and L2 can be different or the same;
CH2 and CH3 are human immunoglobulin CH2 and CH3 domains, respectively; and
Cyt is a cytokine polypeptide or portion thereof that binds to a cytokine receptor present on NK cells, optionally wherein Cyt is a wild-type or variant human IL-2, IL-15, IL-21, IL-7, IL-27, IL-12, IL-18, IFN-α or IFN-β polypeptide.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 27)

The protein of any one of claims 1-17, 19-24 or 27, having the domain arrangement:

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 18, 19, 20, 21, 22, 23)

The protein of any one of claims 1-14 or 18-23, wherein the protein is an isolated heterodimeric polypeptide comprising:
(a) a first polypeptide chain comprising, from N- to C-terminus, a first variable domain (V), a CH1 of Cκ constant region, a Fc domain or portion thereof, a second variable domain and a third variable domain, and a wild-type or variant cytokine that binds to a cytokine receptor present on NK cells; and
(b) a second polypeptide chain comprising, from N- to C-terminus, a first variable domain (V), a CH1 or CK constant region, and a Fc domain or portion thereof, wherein the CH1 or Cκ constant region is selected to be complementary to the CH1 or Cκ constant region of the first polypeptide chain such that the first and second polypeptides form a CH1-Cκ heterodimer in which the first variable domain of the first polypeptide chain and the first variable domain of the second polypeptide form a first antigen binding domain; and wherein the second variable domain and third variable domain forms a second antigen binding domain.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 18, 19, 20, 21, 22, 23, 29)

The protein of any one of claims 1-14, 18-23 or 29, wherein the protein is a heterodimer having a polypeptide chain 1 and 2:
wherein:
Va-1, Vb-1, Va-2 and Vb-2 are each a VH domain or a VL domain, wherein one of Va-1 and Vb-1 is a VH and the other is a VL and wherein Va-1 and Vb-1 form a first antigen binding domain (ABD) that binds an antigen of interest, wherein one of Va-2 and Vb-2 is a VH and the other is a VL and wherein Va-2 and Vb-2 form a second ABD that binds NKp46;
CH1 is a heavy chain constant domain 1 and CL is a light chain constant domain;
one of (CH1 or CL)a and (CH1 or CL)b is a CH1 and the other is a CL such that a (CH1/CL) pair is formed;
Hinge is an immunoglobulin hinge region or portion thereof;
L1, L2 and L3 are each a domain linker, wherein L1, L2 and L3 can be different or the same;
CH2 and CH3 are human immunoglobulin CH2 and CH3 domains, respectively; and
Cyt is a cytokine polypeptide or portion thereof that binds to a cytokine receptor present on NK cells, optionally wherein Cyt is a wild-type or variant human IL-2, IL-15, IL-21, IL-7, IL-27, IL-12, IL-18, IFN-α or IFN-β polypeptide.

### Claim 31

The protein of any one of the above claims, wherein the ABD that binds to an antigen of interest comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein the VH region comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 97%, 98% or 99% identity, to the amino acid sequence of SEQ ID NOS: 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154 or any of 236-313, and wherein the VL comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 97%, 98% or 99% identity, to the amino acid sequence of SEQ ID NOS: 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155 or any of 314-403.

### Claim 32

The protein of any one of the above claims, wherein the ABD that binds to NKp46 comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein the VH region comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 97%, 98% or 99% identity, to the amino acid sequence of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 112, 113, 115, 116, 117, 119, 120, 121, 123, 124, 125, 127, 128, 129 or any of 236-313, and wherein the VL comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 97%, 98% or 99% identity, to the amino acid sequence of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 114, 118, 122, 126, 130 or any of 314-403.

### Claim 33

The protein of any one of the above claims, wherein an Fc domain comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the Fc polypeptide of any of SEQ ID NOS: 160-165.

### Claim 34

The protein of any one of the above claims, wherein a CH1 domain comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the CH1 polypeptide of any of SEQ ID NOS: 156.

### Claim 35

The protein of any one of the above claims, wherein a CK or CL domain comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the CK polypeptide of any of SEQ ID NOS: 156.

### Claim 36

The protein of any one of the above claims, wherein the multispecific protein comprises:
(a) an ABD that binds to the antigen of interest, wherein the ABD comprises an scFv or Fab,
a. wherein the scFv comprises a VH comprising an amino acid sequence at least 90% identical to a sequence selected from SEQ ID NOS: 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154 and any of 236-313, a domain linker, and a VL comprising an amino acid sequence at least 90% identical to a sequence selected from SEQ ID NOS: 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155 and any of 314-403; and
b. wherein the Fab comprises one VH comprising an amino acid sequence at least 90% identical to a selected from SEQ ID NOS: 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154 and any of 236-313, one VL comprising an amino acid sequence at least 90% identical to a sequence selected from SEQ ID NOS: 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155 and any of 314-403, one human CH1 domain comprising an amino acid sequence at least 90% identical to SEQ ID NO: 156 and one human CL domain comprising an amino acid sequence at least 90% identical to SEQ ID NOS: 159, wherein the VH is fused to one of the CH1 or CL domains, and the VL is fused to the other of the CH1 or CL domains,
(b) an ABD that binds to a human NKp46 polypeptide, wherein the ABD comprises an scFv or Fab,
a. wherein the scFv comprises a VH comprising an amino acid sequence at least 90% identical to a sequence selected from SEQ ID NOS: 3, 5, 7, 9, 11, 13, 112, 113, 115, 116, 117, 119, 120, 121, 123, 124, 125, 127, 128, 129 and any of 236-313, a domain linker, and a VL comprising an amino acid sequence at least 90% identical to a sequence selected from SEQ ID NOS: 4, 6, 8, 10, 12, 14, 114, 118, 122, 126, 130 and any of 314-403; and
b. wherein the Fab comprises one VH comprising an amino acid sequence at least 90% identical to a selected from SEQ ID NOS: 3, 5, 7, 9, 11, 13, 112, 113, 115, 116, 117, 119, 120, 121, 123, 124, 125, 127, 128, 129 and any of 236-313, one VL comprising an amino acid sequence at least 90% identical to a sequence selected from SEQ ID NOS: 4, 6, 8, 10, 12, 14, 114, 118, 122, 126, 130 and any of 314-403, one human CH1 domain comprising an amino acid sequence at least 90% identical to SEQ ID NO: 156 and one human CL domain comprising an amino acid sequence at least 90% identical to SEQ ID NOS: 159, wherein the VH is fused to one of the CH1 or CL domains, and the VL is fused to the other of the CH1 or CL domains,
(c) a Fc domain dimer comprising a first and second Fc monomer wherein each Fc monomer comprises an amino acid sequence at least 80% or 90% identical to a sequence selected from SEQ ID NOS: 160-165; and
(d) a cytokine polypeptide comprising an amino acid sequence at least 80% or 90% identical to a sequence selected from SEQ ID NOS: 404-439, or to a contiguous sequence of at least 40, 50, 60, 70, 80 or 100 amino acid residues thereof, fused, via a domain linker, to the C-terminus of one of the polypeptide chains of the multispecific protein.

### Claim 37

The protein of any one of the above claims, wherein the target cell is a tumor cell.

### Claim 38

The protein of any one of the above claims, wherein the antigen of interest is a cancer antigen.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The protein of any one of claims 1-37, wherein the antigen of interest is expressed by an infectious agent or infected cell.

### Claim 40

The protein of any one of the above claims, wherein the multispecific protein competes for binding to a NKp46 polypeptide with a monoclonal antibody comprising the NKp46-1, NKp46-2, NKp46-3, NKp46-4, NKp46-6 or NKp46-9 VH and VL domains.

### Claim 41

The protein of any one of the above claims, wherein the multispecific protein has decreased binding to a mutant NKp46 polypeptide selected from the group consisting of:
(a) a mutant NKp46 polypeptide having a mutation at residues R101, V102, E104 and/or L105 compared to binding to the wild-type NKp46;
(b) a mutant NKp46 polypeptide having a mutation any one or more of the residues K41, E42, E119, Y121 and/or Y194 compared to binding to the wild-type NKp46; and
(c) a mutant NKp46 polypeptide having a mutation any one or more of the residues P132, E133, 1135, and/or S136 compared to binding to the wild-type NKp46.

### Claim 42

The protein of any one of the above claims, wherein the antigen binding domain that binds NKp46 comprises:
(a) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO: 3 and a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO: 4;
(b) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO: 5 and a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO: 6;
(c) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO: 7 and a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO: 8;
(d) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO: 9 and a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO: 10;
(e) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO: 11 and a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO: 12; or
(f) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO: 13 and a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO: 14.

### Claim 43

A pharmaceutical composition comprising a multispecific protein of any one of the above claims, and a pharmaceutically acceptable carrier or adjuvant.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

A recombinant cell which expresses at one, two, three of four of (or all of) the polypeptide chains of a multispecific protein according to any one of claims 1-42.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

A method of preparing an NK cell composition, the method comprising incubating or contacting NK cells, optionally isolated NK cells, in vitro, with a multispecific protein according to any one of claims 1-42.

### Claim 46 (depends on 45)

A composition of NK cells obtained according to the method of claim 45.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 46)

Use of a protein or composition of any one of claims 1-42, 43 or 46 as a medicament for the treatment of disease and/or in the manufacture of a medicament for the treatment of disease.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

A method of potentiating NK cell activation, cytotoxicity and/or proliferation of NKp46+CD16+ NK cells and/or NKp46+CD16− NK cells in a subject having a disease, the method comprising administering to the subject a multispecific protein according to any of claims 1-42.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

A method delivering or bringing a highly potent cytokine to NK cells and/or to a tumor in a subject having a disease, optionally further with reduced toxicity, the method comprising administering to the subject a multispecific protein according to any of claims 1-42.

### Claim 50 (depends on 45, 46, 47, 48, 49)

The method or use of claims 45-49, wherein the cytokine is a variant or wild-type cytokine or cytokine fragment thereof that retains at least 70%, 80% or 90% of the affinity for its cytokine receptor present on NK cells, compared to the wild-type cytokine counterpart.

### Claim 51 (depends on 45, 46, 47, 48, 49, 50)

The method or use of claims 45-50, wherein the multispecific protein (or the cytokine when included in the multispecific protein) exhibits an EC50 for cytokine pathway signaling in NK cells that is lower than that observed with the cytokine alone or in a protein in which the NKp46 ABD and/or a CD16 ABD are replaced by a control ABD, optionally wherein the EC50 for cytokine pathway signaling in NK cells is at least 10-fold or 100-fold lower, optionally wherein cytokine pathway signaling is assessed by bringing the cytokine into contact with an NK cell and measuring STAT phosphorylation in the NK cells.

### Claim 52 (depends on 47, 48, 49, 50, 51)

The use of claims 47-51, wherein the disease is a cancer or infectious disease.

### Claim 53 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

A method of making a heteromultimeric protein, comprising:
(a) providing a first nucleic acid encoding at least a first polypeptide chain according to any of claims 14-23 or 29-42;
(b) providing a second nucleic acid encoding at least a second polypeptide chain according to any of claims 14-23 or 29-42; and
(c) expressing said first and second nucleic acids in a host cell to produce a protein comprising said first and second polypeptide chains, respectively; loading the protein produced onto an affinity purification support, optionally a Protein-A support, and recovering the heteromultimeric protein.

### Claim 54 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

A method of making a heteromultimeric protein, comprising:
(a) providing a first nucleic acid encoding a first polypeptide chain according to any of claims 14-28 or 31-42;
(b) providing a second nucleic acid encoding a second polypeptide chain according to any of claims 14-28 or 31-42;
(c) providing a third nucleic acid comprising a third polypeptide chain according to any of claims 14-28 or 31-42; and
(d) expressing said first, second and third nucleic acids in a host cell to produce a protein comprising said first, second and third polypeptide chains, respectively; loading the protein produced onto an affinity purification support, optionally a Protein-A support, and recovering the heteromultimeric protein.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

A method for identifying or evaluating a polypeptide, comprising the steps of:
(a) providing nucleic acid(s) encoding one of more polypeptides of a protein of any of claims 1-42;
(b) expressing said nucleic acids in a host cell to produce said proteins, respectively; and recovering said protein; and
(c) evaluating the protein produced for a biological activity of interest.
